Grifols, S.A. (GRFS) to Issue Special Dividend of $0.09 on July 9th

Grifols, S.A. (NASDAQ:GRFS) declared a special dividend on Friday, June 19th. Shareholders of record on Thursday, July 2nd will be paid a dividend of 0.0945 per share by the biotechnology company on Thursday, July 9th. The ex-dividend date is Thursday, July 2nd.

Grifols has a dividend payout ratio of 19.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Grifols to earn $1.34 per share next year, which means the company should continue to be able to cover its $0.21 annual dividend with an expected future payout ratio of 15.7%.

Grifols Stock Down 0.8%

Shares of NASDAQ:GRFS opened at $7.33 on Tuesday. The company has a market capitalization of $4.99 billion, a PE ratio of 38.58, a P/E/G ratio of 0.29 and a beta of 0.65. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. Grifols has a twelve month low of $7.08 and a twelve month high of $11.14. The firm has a 50 day simple moving average of $7.80 and a 200-day simple moving average of $8.45.

Grifols (NASDAQ:GRFS) last posted its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. The firm had revenue of $2.32 billion for the quarter. On average, equities analysts predict that Grifols will post 1.06 EPS for the current fiscal year.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.